Pro Medicus Ltd (ASX: PME) has done something it has rarely done at this scale before.
The company has signed a binding Heads of Agreement with Echo IQ Ltd (ASX: EIQ), a Sydney-based AI cardiology company, to expand its AI-driven cardiology solutions and broaden its commercial reach in the United States.
On paper, this is a small transaction for a company with a market capitalisation in the tens of billions.
The potential that lies underneath is what deserves attention.
Image source: Getty Images
What the Pro Medicus AI cardiology deal involves
Pro Medicus will make an initial $10 million investment in Echo IQ through secured convertible notes. The company retains the option to invest a further $10 million once Echo IQ's heart failure algorithm, EchoSolv HF, receives clearance from the US Food and Drug Administration.
Pro Medicus also becomes the proposed US reseller of Echo IQ's EchoSolv product suite. This should plug an AI-powered cardiac diagnostic tool directly into the same hospital network that already runs its Visage 7 imaging platform.
CEO Sam Hupert framed the move as part of a deliberate strategy, stating:
In addition to providing financial backing, we are looking to offer our Visage 7 Cardiology customers the option of Echo IQ's technology. This is in line with our AI strategy of offering a curated suite of algorithms that will be a mixture of algorithms created by us, those created in conjunction with our clinical partners and third party algorithms such as Echo-IQ.
Definitive legal documentation is still being finalised, with completion expected within the coming weeks.
Why this deal matters more than its size suggests
Pro Medicus has spent the past 18 months landing landmark Full Stack contracts with major US health systems. The company's cardiology modules are increasingly attached at the point of first sale.
Bolting Echo IQ's AI diagnostic layer directly onto Pro Medicus' existing distribution network gives Pro Medicus a capability it does not have to build in-house, sitting natively alongside the workflow its customers already use every day.
This deal positions Pro Medicus as acquiring a low-cost option on AI-led cardiology imaging without diluting its own research and development.
The more pessimistic view states that every legacy imaging vendor in North America is now racing to add its own AI partners. This may narrow the window in which a reseller deal like this one carries exclusive competitive value.
What it means for Pro Medicus shares
Pro Medicus shares were up 3.5% to $185.30 on the news, adding to a rally that has lifted the stock roughly 50% since mid-May. Year-to-date, however, shares still remain down.
This partial recovery follows a difficult few months for the stock. This downturn was driven by broader fears that AI would disrupt rather than enhance imaging software businesses.
This deal is a direct rebuttal to that fear. Pro Medicus is not being disrupted by AI cardiology tools. Rather, it is bringing them in-house and reselling them to its own customer base.
What it means for Echo IQ shareholders
The reaction in Echo IQ shares has been even more dramatic.
Echo IQ shares jumped 28% to a record high of $1.58.
Echo IQ CEO Dustin Haines called the deal:
A transformational milestone for Echo IQ and a significant validation of both our technology and long-term commercial strategy, while also providing exceptional financial flexibility to accelerate our commercialisation activities in the US.
For a small-cap AI company, validation and distribution from one of Australia's most successful healthcare technology exporters is about as strong an endorsement as the market could ask for.
Foolish takeaway
The dollar value of this deal is immaterial to Pro Medicus's balance sheet.
The strategic message is not.
By investing in and reselling third-party AI cardiology technology rather than treating it as a competitive threat, Pro Medicus is reinforcing the thesis that AI strengthens its moat rather than eroding it.
For a stock that spent the first half of 2026 being sold down on exactly the opposite fear, that distinction is the real reason this deal matters.
